Takeda to sell dengue vaccine abroad, starting with Indonesia

Japan's first global vaccine can be used for children younger than existing shots

Takeda is investing 130 million euros ($132 million) to build a plant in Germany that can make 50 million doses of its dengue vaccine a year. (Photo courtesy of the company)

NORIYUKI TAKADA, Nikkei staff writer

August 17, 2022 18:00 JST

TOKYO -- A dengue fever vaccine developed by Japan's Takeda Pharmaceutical has completed clinical trials and is expected to be approved in Indonesia soon, Nikkei has learned.

This will be the first global launch of a vaccine by a Japanese company. Takeda has already applied for approval of its dengue vaccine in Asia and South America, as well as Europe. The company aims to market the vaccine in about 30 countries and generate annual sales of $1.6 billion.